Pregnancy outcome in cancer patients. Experience in a large cooperative group

摘要: To evaluate the potential teratogenicity and mutagenicity of modern cancer treatment, authors enumerated from a cooperative clinical trial group 133 pregnancies in 66 women with malignant neoplasms (53% Hodgkin's disease, 26% other lymphomas leukemia, 21% solid tumors). The gestations were divided into following groups: Group 1, 43 ending before therapy; 2, therapy given at conception or during 32 pregnancies; 3, 58 after therapy. Although total frequencies abnormalities similar Groups 1 2 (23% 35 not electively aborted 28% 25, respectively), there slightly more elective abortions birth defects related to radiation exposure susceptible time gestation 2. Still, eight normal infants among ten fetuses who liveborn had first trimester chemotherapy alone; so, drug early pregnancy is inevitably teratogenic. apparent surprising excess abnormal outcomes 40% 50 pregnancies, was due low weight premature terminations pregnancy, rather than an congenital anomalies. type unfavorable 3 their concentration year posttherapy suggested they could represent factors (e.g., uterine hormonal) that normally maintain gestations, genetic damage oocytes. Limitations data, collected by mail physicians patients, included biases self-reporting statistical power. Prospective study, probably through interinstitutional collaboration, seems necessary, if accurate estimates are be made frequency certain outcomes, such as spontaneous abortion minor